登录

Solipharma Closed On 260 Million Yuan of Financing

作者: Mailman 2019-09-10 16:57
领业医药
http://www.solipharma.com/
企业数据由 动脉橙 提供支持
原料药的晶型筛选和结晶工艺开发及制剂中原料药固体型态的控制及检测服务提供商 | 战略融资 | 运营中
中国-浙江
2019-08-29
融资金额:RMB¥2.6亿
金石亚药
查看

According to ChinaVenture, Solipharma recently completed 260 million yuan of financing, jointly invested by Goldstone Orient Company, Hangzhou Pitaya Investment Management co., LTD, Beijing Yinhe Dingfa Venture Investment co., LTD., Shenzhen Pantong Investment Management co., LTD, Hangzhou Hi-Tech Investment co., LTD. and personal investor Gao Yaping.


This financing will be mainly used in three aspects, including the development of existing and new product R&D pipelines, the acquisition and continuous operation recognized by the investors and Solipharma, and the supplement of the working capital for normal production and management.


SoliPharma is a specialty pharmaceutical company, founded in 2010 by Dr. Sheng Xiaoxia, an expert on the Chinese "Thousand Talents Plan". The company’s mission is to “bring challenging molecules to global markets” faster and better through SoliTech® Solutions.  It provides comprehensive solutions to our clients worldwide from early API development (solid form screening/crystallization process) to drug product development (formulation/analytical chemistry).


The Goldstone Orient Company regarded this cooperation as an extension of the internal research and development platform to improve its research and development strength.


>>>>
About Goldstone Orient Company


Goldstone Orient Company has focused on developing advanced plastic composite pipe technology and putting it into applications. The company can provide the reinforced pipe total solution for customers from structure design, processing, engineering installation to standard documentations. Goldstone has led the Chinese steel reinforced pipe industry and participated in formulating numbers of national standards to promote the development of the industry. 


>>>>
About Hangzhou Hi-Tech Investment 


Hangzhou Hi-Tech Investment is a comprehensive state-owned investment and financing company. With a registered capital of 2.6 billion yuan, it ranks 26th among registered venture capital enterprises in China. It manages funds including Hangzhou Venture Investment Guidance Fund, Angel Investment Guidance Fund, policy guarantee and provides other financing services.

相关赛道 化学制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

谷歌风投、OrbiMed等多家顶级投资机构,他们在海外投什么医疗企业

Alphamab Oncology Raises $234 Million in Hong Kong IPO, Climbs 35% in First Trading Session

China's Biotech Start-up Hui-Gene Therapeutics Raises $14M in Series A financing

Yiming Cell Closes on Tens of Million Yuan Angel Round Financing

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

生物技术公司PathoQuest完成800万欧元融资,开发基因测序平台

2019-09-10
下一篇

Jiabao Kangle Snared Tens of Millions of Yuan in Two Rounds of Financing

2019-09-10